| Dr Kelly Own, MD | |
|
3801 S National Ave Ste 900, Springfield, MO 65807-5210 | |
| (417) 885-3888 | |
| (417) 881-7268 |
| Full Name | Dr Kelly Own |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 12 Years |
| Location | 3801 S National Ave Ste 900, Springfield, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275890956 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 04-40391 (Kansas) | Secondary |
| 208100000X | Physical Medicine & Rehabilitation | 2017031975 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cox Medical Centers | Springfield, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Springfield Neurological And Spine Institute | 3375722945 | 13 |
News Archive
4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended resminostat for designation as orphan medicinal product for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
Diamyd Medical AB, to date no drug related Serious Adverse Events have been reported by any patient included in Diamyd's Phase I clinical trial investigating NP2 as a potential therapy for chronic pain. Based upon the Phase I findings to date, the company is planning a multi-center, randomized, double-blind, placebo controlled Phase II clinical trial with NP2 in the United States.
Mayo Clinic researchers have found a way to revive immunity in mice that have abnormal or deficient immune systems. The discovery may lead to a means of restoring immunity to individuals with immunodeficiency diseases such as AIDS and cancer.
The East African profiles Seth Berkley, the new CEO of the GAVI Alliance and founder and former CEO of the International AIDS Vaccine Initiative.
Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing Teva's New Drug Application (NDA) for beclomethasone dipropionate hydrofluoroalkane (BDP Nasal HFA), a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).
› Verified 8 days ago
| Entity Name | Springfield Neurological And Spine Institute |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508169764 PECOS PAC ID: 3375722945 Enrollment ID: O20110128000018 |
News Archive
4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended resminostat for designation as orphan medicinal product for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
Diamyd Medical AB, to date no drug related Serious Adverse Events have been reported by any patient included in Diamyd's Phase I clinical trial investigating NP2 as a potential therapy for chronic pain. Based upon the Phase I findings to date, the company is planning a multi-center, randomized, double-blind, placebo controlled Phase II clinical trial with NP2 in the United States.
Mayo Clinic researchers have found a way to revive immunity in mice that have abnormal or deficient immune systems. The discovery may lead to a means of restoring immunity to individuals with immunodeficiency diseases such as AIDS and cancer.
The East African profiles Seth Berkley, the new CEO of the GAVI Alliance and founder and former CEO of the International AIDS Vaccine Initiative.
Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing Teva's New Drug Application (NDA) for beclomethasone dipropionate hydrofluoroalkane (BDP Nasal HFA), a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kelly Own, MD Po Box 9434, Springfield, MO 65801-9434 Ph: (417) 882-1207 | Dr Kelly Own, MD 3801 S National Ave Ste 900, Springfield, MO 65807-5210 Ph: (417) 885-3888 |
News Archive
4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended resminostat for designation as orphan medicinal product for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
Diamyd Medical AB, to date no drug related Serious Adverse Events have been reported by any patient included in Diamyd's Phase I clinical trial investigating NP2 as a potential therapy for chronic pain. Based upon the Phase I findings to date, the company is planning a multi-center, randomized, double-blind, placebo controlled Phase II clinical trial with NP2 in the United States.
Mayo Clinic researchers have found a way to revive immunity in mice that have abnormal or deficient immune systems. The discovery may lead to a means of restoring immunity to individuals with immunodeficiency diseases such as AIDS and cancer.
The East African profiles Seth Berkley, the new CEO of the GAVI Alliance and founder and former CEO of the International AIDS Vaccine Initiative.
Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing Teva's New Drug Application (NDA) for beclomethasone dipropionate hydrofluoroalkane (BDP Nasal HFA), a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).
› Verified 8 days ago
Jessica Anne Hanson, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3555 S National Ave, Springfield, MO 65807 Phone: 417-269-6868 | |
Dr. Julia E Griesemer, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1235 E Cherokee St, Springfield, MO 65804 Phone: 417-820-8364 Fax: 417-820-7136 | |
Logan Prescott, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 3545 S National Ave, Springfield, MO 65807 Phone: 417-269-3282 | |
Dr. Jesse W Neeley, DO Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 5904 S Southwood Rd, Springfield, MO 65804 Phone: 877-749-7428 Fax: 512-628-3314 | |
Dr. Charles C Mauldin Jr., M.D. Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1308 N Glenstone Ave, Springfield, MO 65802 Phone: 417-864-4100 Fax: 417-863-8697 | |
Dr. Ronald J Pak, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1235 E Cherokee St, Springfield, MO 65804 Phone: 417-820-2364 Fax: 417-820-7136 | |
Dr. Thomas B. Corsolini, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 3520 S Culpepper Circle Ste. D, Springfield, MO 65804 Phone: 417-882-7500 Fax: 417-881-2840 |